Listed

Immucell Corp

ICCCNasdaqCIK 811641HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$7.2mRevenue, Q2 FY2026, three months to 2026-06-30$7.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 13, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$7.2mRevenue, Q2 FY2026, three months to 2026-06-30$7.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Report this figure+11.5% on a year earlier
  • Gross margin33.9%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $2.4m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Revenue: $7.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Report this figure−9.8 pts on a year earlier
  • Operating margin26.9%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Revenue: $7.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Report this figure+18.1 pts on a year earlier
  • Net margin25.5%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $1.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Revenue: $7.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Report this figure+17.7 pts on a year earlier
  • Diluted EPS$0.20Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Report this figure+233.3% on a year earlier
  • Free cash flow$2.3mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $3.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001437749-26-027668. Derived: 6-month figure less the 3-month figure.Capital expenditure: $733.9k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001437749-26-027668. Derived: 6-month figure less the 3-month figure.Report this figure+58.0% on a year earlier

Last eight quarters

Full statements
Revenue$7.2mGross margin 33.9%
Diluted EPS$0.20, Q2 FY2026
Free cash flow$2.3m, Q2 FY2026
Immucell Corp, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m6.0Revenue, Q3 FY2024, three months to 2024-09-30$6.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001437749-25-034817.Report this figure7.8Revenue, Q4 FY2024, three months to 2024-12-31$7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Report this figure8.1Revenue, Q1 FY2025, three months to 2025-03-31$8.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Report this figure6.4Revenue, Q2 FY2025, three months to 2025-06-30$6.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Report this figure5.5Revenue, Q3 FY2025, three months to 2025-09-30$5.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001437749-25-034817.Report this figure7.6Revenue, Q4 FY2025, three months to 2025-12-31$7.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Report this figure10.4Revenue, Q1 FY2026, three months to 2026-03-31$10.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Report this figure7.2Revenue, Q2 FY2026, three months to 2026-06-30$7.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Report this figure
Gross margin%26.3%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $1.6m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-13, accession 0001437749-25-034817.Revenue: $6.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001437749-25-034817.Report this figure36.5%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $2.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Report this figure41.6%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $3.4m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Revenue: $8.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Report this figure43.7%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $2.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Revenue: $6.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Report this figure42.9%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $2.4m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-13, accession 0001437749-25-034817.Revenue: $5.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001437749-25-034817.Report this figure38.2%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $2.9m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Revenue: $7.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Report this figure45.0%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $4.7m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Revenue: $10.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Report this figure33.9%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $2.4m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Revenue: $7.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Report this figure
Operating margin%(9.6%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$574.9k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001437749-25-034817.Revenue: $6.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001437749-25-034817.Report this figure8.0%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $621.4k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Report this figure13.9%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $1.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Revenue: $8.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Report this figure8.8%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $569.6k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Revenue: $6.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Report this figure0.4%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $20.1k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001437749-25-034817.Revenue: $5.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001437749-25-034817.Report this figure(0.8%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$58.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Revenue: $7.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Report this figure19.0%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $2.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Revenue: $10.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Report this figure26.9%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Revenue: $7.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Report this figure
Net margin%(11.7%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$701.7k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001437749-25-034817.Revenue: $6.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001437749-25-034817.Report this figure6.6%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $514.6k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Report this figure17.9%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $1.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Revenue: $8.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Report this figure7.8%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $501.9k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Revenue: $6.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Report this figure(2.5%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$139.7k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001437749-25-034817.Revenue: $5.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001437749-25-034817.Report this figure(37.4%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Revenue: $7.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Report this figure18.7%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $1.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Revenue: $10.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Report this figure25.5%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $1.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Revenue: $7.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Report this figure
Diluted EPS$ per share(0.09)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001437749-25-034817.Report this figurenot reported (Diluted EPS not reported)0.16Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Report this figure0.06Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Report this figure(0.02)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001437749-25-034817.Report this figurenot reported (Diluted EPS not reported)0.21Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Report this figure0.20Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001437749-26-027668.Report this figure
Free cash flow$m(0.7)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$639.3k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001437749-25-034817. Derived: 9-month figure less the 6-month figure.Capital expenditure: $88.4k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001437749-25-034817. Derived: 9-month figure less the 6-month figure.Report this figure(0.2)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$3.1k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Capital expenditure: $196.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Report this figure1.2Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $1.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Capital expenditure: $329.1k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Report this figure1.4Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $1.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001437749-26-027668. Derived: 6-month figure less the 3-month figure.Capital expenditure: $155.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001437749-26-027668. Derived: 6-month figure less the 3-month figure.Report this figure(1.8)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$1.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001437749-25-034817. Derived: 9-month figure less the 6-month figure.Capital expenditure: $593.9k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001437749-25-034817. Derived: 9-month figure less the 6-month figure.Report this figure0.3Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $482.5k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Capital expenditure: $172.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-30, accession 0001437749-26-010339. Derived: 12-month figure less the 9-month figure.Report this figure3.4Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $3.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Capital expenditure: $177.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001437749-26-017045.Report this figure2.3Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $3.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001437749-26-027668. Derived: 6-month figure less the 3-month figure.Capital expenditure: $733.9k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001437749-26-027668. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$27.6mGross margin 41.4%
Diluted EPS−$0.12, FY2025
Free cash flow$1.2m, FY2025
Immucell Corp, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m19.2Revenue, FY2021, twelve months to 2021-12-31$19.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2023-11-13, accession 0001213900-23-086092.Report this figure18.6Revenue, FY2022, twelve months to 2022-12-31$18.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-04-01, accession 0001213900-24-028718.Report this figure17.5Revenue, FY2023, twelve months to 2023-12-31$17.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-04-01, accession 0001213900-24-028718.Report this figure26.5Revenue, FY2024, twelve months to 2024-12-31$26.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001437749-26-010339.Report this figure27.6Revenue, FY2025, twelve months to 2025-12-31$27.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001437749-26-010339.Report this figure
Gross margin%45.0%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $8.7m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2023-11-13, accession 0001213900-23-086092.Revenue: $19.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2023-11-13, accession 0001213900-23-086092.Report this figure41.2%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $7.6m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2024-11-13, accession 0001213900-24-097450.Revenue: $18.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-04-01, accession 0001213900-24-028718.Report this figure22.1%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $3.9m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-03-28, accession 0001013762-25-004072.Revenue: $17.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-04-01, accession 0001213900-24-028718.Report this figure30.0%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $7.9m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-30, accession 0001437749-26-010339.Revenue: $26.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001437749-26-010339.Report this figure41.4%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $11.4m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-30, accession 0001437749-26-010339.Revenue: $27.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001437749-26-010339.Report this figure
Operating margin%1.3%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $257.4k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2023-11-13, accession 0001213900-23-086092.Revenue: $19.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2023-11-13, accession 0001213900-23-086092.Report this figure(12.4%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$2.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001213900-24-097450.Revenue: $18.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-04-01, accession 0001213900-24-028718.Report this figure(32.9%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$5.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-28, accession 0001013762-25-004072.Revenue: $17.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-04-01, accession 0001213900-24-028718.Report this figure(6.2%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$1.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001437749-26-010339.Revenue: $26.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001437749-26-010339.Report this figure6.0%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $1.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001437749-26-010339.Revenue: $27.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001437749-26-010339.Report this figure
Net margin%(0.4%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$78.3k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-29, accession 0001213900-23-024080.Revenue: $19.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2023-11-13, accession 0001213900-23-086092.Report this figure(13.4%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$2.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-04-01, accession 0001213900-24-028718.Revenue: $18.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-04-01, accession 0001213900-24-028718.Report this figure(33.1%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$5.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-28, accession 0001013762-25-004072.Revenue: $17.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-04-01, accession 0001213900-24-028718.Report this figure(8.1%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$2.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001437749-26-010339.Revenue: $26.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001437749-26-010339.Report this figure(3.8%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$1.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001437749-26-010339.Revenue: $27.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001437749-26-010339.Report this figure
Diluted EPS$ per share(0.01)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-03-29, accession 0001213900-23-024080.Report this figure(0.32)Diluted EPS, FY2022, twelve months to 2022-12-31−$0.32 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-04-01, accession 0001213900-24-028718.Report this figure(0.75)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-28, accession 0001013762-25-004072.Report this figure(0.26)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-30, accession 0001437749-26-010339.Report this figure(0.12)Diluted EPS, FY2025, twelve months to 2025-12-31−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-30, accession 0001437749-26-010339.Report this figure
Free cash flow$m(1.7)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $954.2k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-29, accession 0001213900-23-024080.Capital expenditure: $2.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-29, accession 0001213900-23-024080.Report this figure(5.5)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-04-01, accession 0001213900-24-028718.Capital expenditure: $4.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-04-01, accession 0001213900-24-028718.Report this figure(6.6)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$4.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-28, accession 0001013762-25-004072.Capital expenditure: $1.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-28, accession 0001013762-25-004072.Report this figure(0.1)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $357.9k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001437749-26-010339.Capital expenditure: $465.7k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-30, accession 0001437749-26-010339.Report this figure1.2Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $2.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001437749-26-010339.Capital expenditure: $1.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-30, accession 0001437749-26-010339.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Immucell Corp
FundQuarter endedReported valueSharesPut or callChange on the quarter before
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$2.7m268,130Added+7,803
MORGAN STANLEY2026-06-30$2.4m233,910Added+12,194
RENAISSANCE TECHNOLOGIES LLC2026-06-30$1.7m171,089Added+19,300
Cresset Asset Management, LLC2026-06-30$1.4m135,267Unchanged
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$726.5k72,270Added+6,505
DIMENSIONAL FUND ADVISORS LP2026-06-30$587.4k58,452Added+2,422
Bleichroeder LP2026-06-30$502.5k50,000Reduced−51,594
Steadtrust LLC2026-06-30$456.0k45,370Reduced−9,000
Mesirow Financial Investment Management, Inc.2026-06-30$426.9k42,481Unchanged
CITADEL ADVISORS LLC2026-06-30$407.1k40,503Added+4,807

Recent filings

All 565 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Immucell Corp, recent filings
FiledFormWhat it isAccession number
2026-10-1310:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001437749-26-032465
2026-08-1320:08 ET10-QQuarterly reportPeriod 2026-06-300001437749-26-027668
2026-08-1320:07 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001437749-26-027667
2026-07-0920:08 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001437749-26-023199
2026-06-1718:19 ET8-K5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001437749-26-020926
2026-06-1020:05 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001437749-26-020154
2026-05-1420:09 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001437749-26-017049
2026-05-1420:07 ET10-QQuarterly reportPeriod 2026-03-310001437749-26-017045
2026-05-1320:07 ET10-K/AAnnual report, amendedPeriod 2025-12-310001437749-26-016719
2026-05-0821:00 ET8-K1.01 Entry into a material agreement0001437749-26-015945

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 30, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
811641
Tickers
ICCC
Exchange
Nasdaq
SIC code
2835 In Vitro & In Vivo Diagnostic Substances
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:25 ET. Listed shows no prices and gives no investment advice.